Decreasing incidence of hepatocellular carcinoma among most racial groups: SEER-22, 2000–2019

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2023-09-30 DOI:10.1002/cam4.6537

Thomas R. O'Brien, Susan S. Devesa, Jill Koshiol, Jorge A. Marrero, Meredith S. Shiels

{"title":"Decreasing incidence of hepatocellular carcinoma among most racial groups: SEER-22, 2000–2019","authors":"Thomas R. O'Brien, Susan S. Devesa, Jill Koshiol, Jorge A. Marrero, Meredith S. Shiels","doi":"10.1002/cam4.6537","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Hepatocellular carcinoma (HCC) incidence was rising in the United States. Previously, using data collected by the Surveillance, Epidemiology, and End Results (SEER) Program through 2017, we found that overall incidence had begun to decline, although not in Black and American Indian/Alaska Native (AI/AN) populations. Utilizing expanded SEER data encompassing ~50% of the population, we examined secular trends and demographic differences in HCC incidence through 2019.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We included cases of HCC diagnosed in adults aged ≥20 years residing in SEER-22 registry areas. We examined case counts, incidence rates (per 100,000 person-years), annual percent changes (APCs), and calendar years when APCs changed significantly.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>HCC incidence increased from 5.56 in 2000 to 8.89 in 2009 (APC, 5.17%), then rose more slowly during 2009–2015 (APC, 2.28%). After peaking at 10.03 in 2015, incidence fell to 9.20 in 2019 (APC, −2.26%). In Asian/Pacific Islanders (A/PI), the decline began in 2007 and accelerated in 2015 (APCs: 2007–2015, −1.84%; 2015–2019, −5.80%). In 2014, incidence began to fall in the White (APC: 2014–2019, −1.11%) and Hispanic populations (APC: 2014–2019, −1.72%). In 2016, rates began to fall in Black individuals (APC: 2016–2019, −6.05%). In the AI/AN population, incidence was highest in 2017, although the subsequent decline was not statistically significant. In 2019, population-specific rates were: White, 6.94; Black, 10.74; A/PI, 12.11; AI/AN, 14.56; Hispanic, 15.48.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>HCC incidence is now decreasing in most US racial/ethnic populations, including among Black individuals. The onset of decline differed among racial/ethnic groups and wide disparities in HCC rates remain.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"12 19","pages":"19960-19967"},"PeriodicalIF":2.9000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.6537","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.6537","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Hepatocellular carcinoma (HCC) incidence was rising in the United States. Previously, using data collected by the Surveillance, Epidemiology, and End Results (SEER) Program through 2017, we found that overall incidence had begun to decline, although not in Black and American Indian/Alaska Native (AI/AN) populations. Utilizing expanded SEER data encompassing ~50% of the population, we examined secular trends and demographic differences in HCC incidence through 2019.

Methods

We included cases of HCC diagnosed in adults aged ≥20 years residing in SEER-22 registry areas. We examined case counts, incidence rates (per 100,000 person-years), annual percent changes (APCs), and calendar years when APCs changed significantly.

Results

HCC incidence increased from 5.56 in 2000 to 8.89 in 2009 (APC, 5.17%), then rose more slowly during 2009–2015 (APC, 2.28%). After peaking at 10.03 in 2015, incidence fell to 9.20 in 2019 (APC, −2.26%). In Asian/Pacific Islanders (A/PI), the decline began in 2007 and accelerated in 2015 (APCs: 2007–2015, −1.84%; 2015–2019, −5.80%). In 2014, incidence began to fall in the White (APC: 2014–2019, −1.11%) and Hispanic populations (APC: 2014–2019, −1.72%). In 2016, rates began to fall in Black individuals (APC: 2016–2019, −6.05%). In the AI/AN population, incidence was highest in 2017, although the subsequent decline was not statistically significant. In 2019, population-specific rates were: White, 6.94; Black, 10.74; A/PI, 12.11; AI/AN, 14.56; Hispanic, 15.48.

Conclusion

HCC incidence is now decreasing in most US racial/ethnic populations, including among Black individuals. The onset of decline differed among racial/ethnic groups and wide disparities in HCC rates remain.

Abstract Image

查看原文本刊更多论文

大多数种族中肝细胞癌发病率下降：SEER-222000-2019。

背景：肝细胞癌（HCC）的发病率在美国呈上升趋势。此前，使用监测、流行病学和最终结果（SEER）项目截至2017年收集的数据，我们发现总体发病率已开始下降，尽管黑人和美洲印第安人/阿拉斯加原住民（AI/AN）的发病率没有下降。利用扩大的SEER数据，包括约50%的人口，我们研究了截至2019年HCC发病率的长期趋势和人口统计学差异。方法：我们纳入了在≥20岁的成年人中诊断的HCC病例居住在SEER-22登记区的年。我们检查了病例数、发病率（每100000人-年）、年百分比变化（APC）和APC显著变化的日历年。结果：HCC发病率从2000年的5.56上升到2009年的8.89（APC，5.17%），然后在2009-2015年缓慢上升（APC，2.28%）。在2015年达到峰值10.03后，2019年发病率降至9.20（APC，-2.26%）。在亚太岛民（A/PI）中，下降始于2007年，并在2015年加速（APC：2007-2015，-1.84%；2015-2019，-5.80%）。2014年，白人（APC：2014-2019，-1.11%）和西班牙裔人群（APC：2014-2019，-1.72%）的发病率开始下降。2016年，黑人的发病率（APC：2016-2019，-6.05%）开始下降。在AI/AN人群中，2017年的发病率最高，尽管随后的下降在统计上并不显著。2019年，特定人群的发病率为：白人，6.94；黑色，10.74；A/PI，12.11；AI/AN，14.56；西班牙裔，15.48。结论：在大多数美国种族/族裔人群中，包括黑人人群中，HCC的发病率正在下降。不同种族/族裔群体的发病率有所下降，HCC发病率仍存在巨大差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.